Cerecor is a Baltimore-based biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases.
The members of our team have extensive pharmaceutical product development and commercialization experience and have played key roles in the development or commercialization of Prozac®, Zyprexa®, Cymbalta®, Nuplazid™ and Abilify®.View Management Team
Interim Chief Executive Officer & Chief Business Officer
Mr. Kaiser serves as Cerecor's Chief Business Officer with responsibilities for corporate strategy, strategic marketing and business development and led the company to acquire CERC-301 in 2013, CERC-501 in 2015, and CERC-611 in 2016. Prior to joining Cerecor, Mr. Kaiser founded Denysias Bioscience, LLC, a biopharmaceutical company focused on developing new therapies for neuropsychiatric disorders, where he served as Chief Executive Officer. At the same time, Mr. Kaiser also served as President of Kaiser & Associates Consulting, a boutique consulting firm providing strategic corporate and commercial expertise to the biopharmaceutical industry. From 2008-2009, Mr. Kaiser served as Vice President of Commercial and Business Development at ACADIA Pharmaceuticals Inc. Before ACADIA, Mr. Kaiser held numerous positions of increasing responsibilities in sales, marketing and general management at Eli Lilly and Company in a career of more than 25 years. At Lilly, Mr. Kaiser led the global commercialization efforts of Prozac®, the global strategic marketing efforts for Cymbalta®, and helped drive the commercial success of Zyprexa® internationally. Mr. Kaiser also led the strategic marketing efforts for the company's CNS development portfolio and co-led the development and execution of the company's CNS strategy. Mr. Kaiser is a member of Cerecor's Senior Management Team and currently serves on the Board of Directors of NHTherapeutics. Mr. Kaiser received his B.S. in pharmaceutical sciences from the James L. Winkle College of Pharmacy at the University of Cincinnati.
Chief Medical Officer and Head, Regulatory Affairs
Dr. Marcus has served as our Chief Medical Officer and Head of Regulatory Affairs since May 2015. He has more than 20 years of experience in the development of neuroscience drugs at both Spinifex Pharmaceuticals, or Spinifex, and Bristol-Myers Squibb. Dr. Marcus was most recently the Chief Medical Officer at Spinifex, where he was responsible for driving clinical development and regulatory strategy of its lead compound for neuropathic pain. Prior to that, Dr. Marcus held various positions at Bristol-Myers Squibb including Group Director of Neuroscience Strategic Unit and Executive Director of Neuroscience Global Clinical Research. In this role, he was Early Development Team Leader for neuropathic pain, schizophrenia and migraine compounds and Life-Cycle Management Team Leader for Abilify®, which included the development of Abilify® for the adjunctive treatment of depression. He has extensive experience in early drug development and possesses both breadth and depth in all of the key functional areas of exploratory and late development, disease biology and regulatory affairs. Dr. Marcus has been recognized within the biopharmaceutical industry for his excellence in overall drug development, innovative strategic leadership and executional excellence while spearheading an industry-leading life cycle management program for Abilify®. In addition to the approval of over 20 New Drug Applications (NDA) and supplemental NDAs globally for Abilify®, Dr. Marcus also led the successful development of Serzone®, an antidepressant. Further, Dr. Marcus has authored more than 80 peer-reviewed publications. Dr. Marcus received his B.A. in Psychology from the University of Virginia. He earned his M.D. from SUNY Buffalo and completed his psychiatry residency and the National Institute of Mental Health research fellowship at Cornell University, New York Hospital-Westchester Division.
Chief Financial Officer
Mariam E. Morris joined Cerecor Pharmaceuticals as Chief Financial Officer in 2015, leading Cerecor through its initial public offering and currently serves as the Company’s Secretary and Treasurer. Mariam is a seasoned financial executive and comes to Cerecor with over 20 years of experience and having owned her own consulting firm for the past six years. While consulting, Mariam worked with several business as out-sourced CFO and CBO roles. Prior to owning her own firm, Mariam was the Chief Financial Officer of Sucampo Pharmaceuticals. (NASDAQ: SCMP). Her years of experience include strategic planning, investor relations, human resources, internal controls for public and private companies, SOX compliance, and oversite of human resources and information technology. Mariam has significant SEC reporting, tax, acquisition, technical accounting, budgeting, treasury, operations and project management experience. She has a Masters in Taxation from Old Dominion University, a B.A. in Accounting from Texas Tech University, and is a member of the AICPA and TSCPA.
VP Clinical Operations & Project Management
Dr. Fraser has served as our Vice President, Clinical Operations and Project Management since October 2012 and Senior Director of Project Management from March 2012 through October 2012. Prior to joining our company, Dr. Fraser served as the Senior Director of Preclinical and Clinical Sciences at Anthera Pharmaceuticals Inc., a biopharmaceutical company, from October 2006 through March 2012. She served in a variety of roles at CV Therapeutics, Inc., a biopharmaceutical company, which was acquired by Gilead Sciences, Inc. in 2009, from June 2000 through October 2006. Dr. Fraser received her B.S. in Zoology from the University of British Columbia, her M.S. in Pharmaceutical Sciences from the University of Montana and her Ph.D. in Pharmacology from the University of Alberta. She has also completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine.